Related Experiment Video

Updated: Sep 11, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Targeting CDK2 for cancer therapy

Erik S Knudsen1, Agnieszka K Witkiewicz2, Ioannis Sanidas3

  • 1Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.

Cell Reports
|August 13, 2025
PubMed

Insights

Targeting cyclin-dependent kinases 2 (CDK2) offers a complex but promising cancer therapy strategy. Tumor genetics and biomarkers like cyclin E guide CDK2 inhibitor effectiveness and combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinases (CDKs) are key regulators of the cell cycle and significant therapeutic targets in oncology.
  • Targeting CDK2 presents unique challenges and opportunities compared to CDK4/6 inhibitors due to its distinct mechanisms of action.

Purpose of the Study:

  • To explore the complexities of targeting CDK2 for cancer therapy.
  • To review the role of biomarkers in predicting response to CDK2 inhibitors.
  • To assess the potential of combining CDK2 inhibitors with other drug classes.

Main Methods:

  • Review of recent studies on CDK2 inhibitors in cancer therapy.
  • Analysis of effector pathways modulated by CDK2 inhibition.
  • Examination of genetic and epigenetic factors influencing treatment response.
  • Evaluation of biomarker data (e.g., cyclin E, p16INK4A) for CDK2 inhibitor efficacy.

Main Results:

  • CDK2 inhibitors impact multiple cell-cycle phases and effector pathways.
  • Tumor genetic and epigenetic profiles determine response to CDK2 inhibitors.
  • Biomarkers such as cyclin E and p16INK4A are crucial for guiding treatment.
  • CDK2 inhibitors show potential for effective combination therapies across various tumor types.

Conclusions:

  • CDK2 inhibition is a complex but viable therapeutic strategy in oncology.
  • Biomarker-driven approaches are essential for optimizing CDK2 inhibitor use.
  • Further research is required to address limitations and toxicities of current and developing CDK2 inhibitors.
Keywords:
CDK inhibitorsCDK2CDK4/6CDKN2ACP: CancerRBcell cyclecyclin D1cyclin Ep16IN4A

More Related Videos

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.5K
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.8K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.7K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.7K